EUVIMEDEUVIMED entdecken
Crossref

KPV and RAPA Self‐Assembled into Carrier‐Free Nanodrugs for Vascular Calcification Therapy

Li Zhang, Dongze Li, Yierpani Aierken, Jie Zhang, Zhenyu Liu, Zipeng Lin, Longqi Jiang, Qingzhu Li, Ya Wu, Yong Liu iD

Advanced Healthcare Materials · 2024-12 · 13 (32)

DOI: 10.1002/adhm.202402320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 10.09.2024. Verfasst von Li Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China. Hauptthemen laut MEDLINE: Nanoparticles, Sirolimus, Vascular Calcification, Autophagy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province of China, Gulin People's Hospital-Southwest Medical University cooperation project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease (CVD) is a leading cause of death globally, and vascular calcification (VC) is an important independent risk factor for predicting CVD. Currently, there are no established therapeutic strategies for the treatment of VC. Although recognized combination therapies of nanomedicines can provide effective strategies for disease treatment, the clinical application of nanomedicines is limited because of their complex preparation processes, low drug loading rates, and unpredictable safety risks. Thus, developing a simple, efficient, and safe nanodrug to simultaneously regulate inflammation and autophagy may be a promising strategy for treating VC. Herein, an anti‐inflammatory peptide (lysine‐proline‐valine peptides, KPV) and the autophagy activator rapamycin (RAPA) are self‐assembled to form new carrier‐free spherical nanoparticles (NPs), which shows good stability and biosafety. In vivo and in vitro, KPV‐RAPA NPs significantly inhibit VC in mice compared to the other treatment groups. Mechanistically, KPV‐RAPA NPs inhibit inflammatory responses and activated autophagy. Therefore, this study indicates that the new carrier‐free KPV‐RAPA NPs have great potential as therapeutic agents for VC combination therapy, which can promote the development of nanodrugs for VC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesSirolimusVascular CalcificationAutophagyAnimalsMiceHumansMice, Inbred C57BLMaleOligopeptides

Stichwörter der Autor:innen

KPVautophagyinflammationrapamycinself‐assembled carrier‐free nanodrugsvascular calcification

Substanzen

SirolimusOligopeptides

Autor:innen und Institutionen

  • Department of Vascular Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
  • Metabolic Vascular Disease Key Laboratory of Sichuan Province, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
  • Department of Endocrinology and Metabolism, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
  • Department of General Surgery, Gulin People's Hospital, Luzhou, 646000, China.
  • Key Laboratory of Medical Electrophysiology, Ministry of Education & Medical Electrophysiological Key Laboratory of Sichuan Province (Collaborative Innovation Center for Prevention of Cardiovascular Diseases), Institute…
  • Department of General Surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.

ORCID-Profile: Yong Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Sichuan Province of China
  • Gulin People's Hospital-Southwest Medical University cooperation project
  • Luzhou-Southwest Medical University cooperation project
  • Foundation of Sichuan Provincial Medical Association
  • Molecular Imaging Hubei Provincial Key Laboratory Open Fund

Zitieren

APA

Zhang, L., Li, D., Aierken, Y., Zhang, J., Liu, Z., Lin, Z., Jiang, L., Li, Q., Wu, Y., & Liu, Y. (2024). KPV and RAPA Self‐Assembled into Carrier‐Free Nanodrugs for Vascular Calcification Therapy. Advanced Healthcare Materials, 13(32). https://doi.org/10.1002/adhm.202402320

Vancouver

Zhang L, Li D, Aierken Y, Zhang J, Liu Z, Lin Z, et al. KPV and RAPA Self‐Assembled into Carrier‐Free Nanodrugs for Vascular Calcification Therapy. Advanced Healthcare Materials. 2024;13(32). doi:10.1002/adhm.202402320

BibTeX
@article{Zhang2024,
  author = {Zhang, Li and Li, Dongze and Aierken, Yierpani and Zhang, Jie and Liu, Zhenyu and Lin, Zipeng and Jiang, Longqi and Li, Qingzhu and Wu, Ya and Liu, Yong},
  title = {KPV and RAPA Self‐Assembled into Carrier‐Free Nanodrugs for Vascular Calcification Therapy},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {32},
  doi = {10.1002/adhm.202402320}
}
Kostenlos starten →